The data is being presented today in an oral presentation at the 2021 ESMO Congress.
- The data is being presented today in an oral presentation at the 2021 ESMO Congress.
- We believe this approach could unlock significant opportunities for SY-5609 and achieve the transformative potential of CDK7 inhibition for people with difficult-to-treat cancers.
- Patients had been heavily pre-treated with as many as eight prior therapies and a median of four prior therapies.
- Syros plans to initiate an expansion cohort evaluating SY-5609 in combination with chemotherapy for the treatment of pancreatic cancer in the fourth quarter of 2021.